Cost-effectiveness of sleep apnea diagnosis and treatment in hospitalized persons with moderate to severe traumatic brain injury - Tsalatsanis A, Dismuke-Greer C, Kumar A, Hoffman J, Monden KR, Magalang U, Schwartz D, Martin AM, Nakase-Richardson R.
OBJECTIVE: To assess the cost-effectiveness of alternative approaches to diagnose and treat obstructive sleep apnea (OSA) in patients with traumatic brain injury (TBI) during inpatient rehabilitation. SETTING: Data collected during the Comparison of Sleep ... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
AHN Physicians Become First in Western Pennsylvania to Implant Central Sleep Apnea Device
AHN Sleep Medicine Division Partners with Network's Cardiovascular Institute to Introduce Groundbreaking Technology for Heart Failure Patients Diagnosed with CSA PITTSBURGH, April 22, 2024 /PRNewswire-PRWeb/ -- "This groundbreaking system has been clinically proven to improve a patient's... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 22, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Tirzepatide Improves Sleep Apnea in Patients With Obesity, Drugmaker Says
(MedPage Today) -- Tirzepatide (Zepbound) injections reduced sleep apnea severity among patients with obesity, regardless of positive airway pressure (PAP) use, according to topline data from two phase III trials.
In the SURMOUNT-OSA 1 study... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 19, 2024 Category: Cardiology Source Type: news
Eli Lilly's weight-loss drug Zepbound could treat sleep apnea
(Source: Reuters: Health)
Source: Reuters: Health - April 18, 2024 Category: Consumer Health News Source Type: news
Hypoglossal Nerve Stimulation Aids Obstructive Sleep Apnea
THURSDAY, April 18, 2024 -- Hypoglossal nerve stimulation (HGNS) helps to reduce obstructive sleep apnea (OSA) but has a decreased response in some patients, according to a study published online April 4 in JAMA Otolaryngology-Head& Neck... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2024 Category: Pharmaceuticals Source Type: news
Drugs Like Ozempic And Mounjaro Could Treat Other Conditions —Here’s What Scientists Are Looking At
GLP-1 drugs like Ozempic, Mounjaro, Zepbound and Wegovy are being explored for treating an array of conditions including sleep apnea, kidney disease, addiction, Parkinson ’s and Alzheimer’s. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 18, 2024 Category: Pharmaceuticals Authors: Robert Hart, Forbes Staff Tags: Business /business Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news topline Source Type: news
Eli Lilly's weight loss drug reduces sleep apnea, study shows
Eli Lilly's weight loss-related drug Zepbound could potentially be used to reduce the severity of sleep apnea in adults with obesity, according to a recent study. Results of a phase three clinical trial, published Wednesday, showed that injections of the drug, either 10 mg or 15 mg, "significantly…#elililly #specificallylilly #zepbound #lilly #jeffemmick #wegovy #fda #novonordisk (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2024 Category: Consumer Health News Source Type: news
Eli Lilly Says Zepbound Can Ease Obstructive Sleep Apnea
WEDNESDAY, April 17, 2024 -- Eli Lilly announced Wednesday that in two company trials, Zepbound was found to ease sleep apnea in adults with obesity.First approved to treat obesity by the U.S. Food and Drug Administration last November, the power... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2024 Category: Pharmaceuticals Source Type: news
Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports
The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk ’s Wegovy. (Source: NYT Health)
Source: NYT Health - April 17, 2024 Category: Consumer Health News Authors: Gina Kolata Tags: Tirzepatide Apnea (Sleep Disorder) Drugs (Pharmaceuticals) Obesity Weight Clinical Trials Eli Lilly and Company Source Type: news
Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Study
stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events in people with obesity. The results bolster Lilly's argument that lowering a person's body weight could improve sleep apnea, a condition in which breathing while sleep becomes more…#lilly #elililly #davidsong #tema #hrts #cpap #resmed #leerinkpartners #davidrisinger #temasong (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2024 Category: Consumer Health News Source Type: news
Eli Lilly ’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two…#zepbound #elilillys #newyorkcity #elililly #fda #osa #pap #jeffemmick #mounjaro #medicare (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2024 Category: Consumer Health News Source Type: news
Weight-Loss Drugs Help Sleep Apnea Symptoms
Eli Lilly & Co.’s weight-loss drug Zepbound improved breathing problems in highly anticipated studies that may convince more insurers to cover the $1,000-a-month treatment.
In two late-stage trials of patients with obstructive sleep apnea, a condition closely linked to obesity, Zepbound reduced the number of times breathing slowed or stopped during sleep by up to 63% from the baseline, Lilly said in a statement Wednesday. The result topped Jefferies analysts’ expectations that the trials would likely show a reduction of about 50% to 55%.
[time-brightcove not-tgx=”true”]
Patients in...
Source: TIME: Health - April 17, 2024 Category: Consumer Health News Authors: Madison Muller/Bloomberg Tags: Uncategorized bloomberg wire healthscienceclimate Source Type: news
Weight-loss Drug Zepbound Eases Sleep Apnea in Company Trials
WEDNESDAY, April 17, 2024 -- Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.First approved to treat... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2024 Category: General Medicine Source Type: news
Eli Lilly's Weight-loss Drug Succeeds in Trials With Sleep Apnea Patients Eli Lilly's Weight-loss Drug Succeeds in Trials With Sleep Apnea Patients
Eli Lilly ' s weight-loss drug helped cut the frequency of irregular breathing in patients with obstructive sleep apnea by as much as 63% on average across two late-stage...Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 17, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Lilly's Weight-loss Drug Reduces Sleep Apnea Severity in Late-stage Trials Lilly's Weight-loss Drug Reduces Sleep Apnea Severity in Late-stage Trials
Eli Lilly said on Wednesday its weight-loss drug helped reduce episodes of irregular breathing associated with a common sleep-related disorder in two late-stage trials,...Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 17, 2024 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news
